The pharmaceutical and biological industry 33 stocks on the list of 100 yuan shares, four pharmaceutical companies closed at more than 300 yuan

Pharmaceutical Network Pharmaceutical Stock Market 100 yuan shares, in the entire A-share market is not much, as one of the signals to determine the heat of the market, has always been the attention of investors.
according to statistics, as of the close of trading on September 25, the Shanghai index closed down 0.12% at 3,219.42, with the average A-share price at 11.19 yuan.
of the new 100 yuan shares, to Shenwan first-class industry classification, the more concentrated industries are pharmaceutical biology, electronics, computers and so on, of which, the pharmaceutical and biological industry has 33 stocks on the list, accounting for 26.61% of the total number of 100 yuan shares.
and Kanghua Bio, Changchun Gaoxin, Consino, Meirui Medical, the new closing price of more than 300 yuan.
Kanghua Bio: The new closing price of 507.50 Kanghua Bio is a comprehensive research, development and operation of integrated vaccine production enterprises, while the current domestic production of human double-body cell rabies vaccine enterprises.
In June this year, Kanghua Bio listed, listed, the company's share price has continued to rise, high to 996 yuan after the start of the correction, the current share price has been broken, only half of the peak, but still more than six times the issue price.
that Kanghua Bio since 2017, the product gradually released, after sales profits are showing rapid growth.
especially this year, the company's half-year sales have been nearly last year's full-year sales, profits are also doubled.
according to reports in recent years, Kanghua Bio's revenue has risen steadily, and its prospecto shows that from 2017 to 2019, Kanghua Bio's operating income reached 262 million yuan, 559 million yuan and 555 million yuan, respectively, and net profit attributable to the company's shareholders reached 0.74 billion yuan, 154 million yuan and 187 million yuan, respectively.
, the proportion of human secondary cell rabies vaccine issuance remained on the rise, the proportion of batch issuance remained low, and there was more room for growth.
, 3.34 percent and 4.04 percent, respectively, were approved for the 2017-2019 year, according to the company's prospectine.
Changchun High-new: The new closing price of 365.70 Changchun High-new as one of the earlier batch of listed companies in Northeast China, currently has Jinsai Pharmaceuticals, Baike Bio, Huakang Pharmaceuticals, High-new Real Estate and other four major business sectors, 2017 and 2018 in the national pharmaceutical industry top 100 ranking 73, 56 respectively.
's share price has risen more than a hundredfold in a decade from 4 yuan per share in 2010 to 400 yuan per share in 2020.
first half of this year, Changchun Gaoxin achieved operating income of 3,917 million yuan, up 15.48 percent year-on-year, net profit of 1.31 billion yuan, up 80.27 percent year-on-year, and recently split its 100 grams bio-impact division, according to
data.
, a growth stock in the pharmaceutical industry over the past few years, now has a market capitalization of more than $180 billion, and its growth hormone business contributes most of its valuation.
But some people in the industry pointed out that looking at the future development of Changchun high-rise, especially the rapid expansion of the body of growth hormone in the future or will face the problem of slowing growth, the future growth space will also be an important factor in determining whether the company's valuation can be maintained or further upgraded.
It is understood that the company is also beginning to make some foreign investment and equity participation, such as the company announced at the end of July to invest 830 million yuan in The city of Changchun, Jilin Province to build innovative pharmaceutical production base, in early July announced that the United States for 28.3 million U.S. high-end generic drugs and children's drug research and development of the Brillian shares, a 42.14 percent stake, to become Changchun Gao new holding subsidiary and achieve the same table.
: The new closing price of 349.00 Consino was registered in Tianjin Binhai New Area in 2009 and is a national high-tech enterprise founded by a team of multinational pharmaceutical executives.
Concino Biology specializes in the development, production and commercialization of high-quality human vaccines, with a worldwide focus on providing solutions to prevent infectious diseases and infections.
23, 2020, Consino began a rebound, rising 20.56 percent in two days.
industry pointed out that Consino's valuation had been significantly overdrawed long before it landed on the A-share market.
three factors supporting its rise in Hong Kong stocks in early 2020, two of which are expected to reverse.
, Consino's founder team.
, the outbreak boosted share prices.
, push up the valuation, for the A-share issue price to determine the "anchor point."
In terms, most of Concino's founders and core technicians have more than 20 years of experience in the biopharmaceutical industry and have worked for global pharmaceutical or biotechnology companies in the development, production and commercialization of international heavy-weight vaccines.
is why, since its listing in March 2019, Consino has been considered to have the growth genes of international vaccine companies and is sought after by capital.
Medical: The new closing price of 330.00 Meirui Medical is the benchmark enterprise of the domestic medical device industry, with a number of products in various sub-sectors accounting for the highest market share at home and abroad.
is also a more successful international pharmaceutical enterprises, overseas business scale in the forefront.
business at home and abroad is facing a good period of policy and market opportunities.
first half of the year, Meirui Medical achieved operating income of 10,564 million yuan, up 28.75 percent year-on-year, and total profit of 3,927 million yuan, up 43.65 percent year-on-year, according to the data.
addition to revenue, in the first half of 2020, the amount of research and development investment reached 1.004 billion yuan, an increase of 29.06 percent year-on-year.
, It is understood that Murray Medical has established a global resource allocation based on research and development innovation platform, with eight research and development centers.
with the support of increased research and development investment, in the first half of 2020, the company launched TM70 telemetry (1.4G), nSP high-end injection pump, nVP high-end infusion pump, nDS high-end pump workstation, nCS infusion central station and other new models, NB300 newborn baby ventilator, 4K endoscope camera New products such as systems and hardcryscopes, DC-80A, DC-90 ultrasound, DC-30 Full HD ultrasound, MX8/7, ME8/7 notebook ultrasound, Resona Hepatus 6W/5W high-end check-up machine and liver fiber machine, as well as a range of bio-chemical and immunologic reagents.